RT Journal Article
SR Electronic
T1 Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.09.03.280370
DO 10.1101/2020.09.03.280370
A1 James S. Terry
A1 Loran BR Anderson
A1 Michael S. Scherman
A1 Carley E. McAlister
A1 Rushika Perera
A1 Tony Schountz
A1 Brian J. Geiss
YR 2020
UL http://biorxiv.org/content/early/2020/09/03/2020.09.03.280370.abstract
AB The global COVID-19 pandemic has caused massive disruptions in every society around the world. To help fight COVID-19, new molecular tools specifically targeting critical components of the causative agent of COVID-19, SARS-Coronavirus-2 (SARS-CoV-2), are desperately needed. The SARS-CoV-2 nucleocapsid protein is a major component of the viral replication processes, integral to viral particle assembly, and is a major diagnostic marker for infection and immune protection. Currently available antibody reagents targeting the nucleocapsid protein were primarily developed against the related SARS-CoV virus and are not specific to SARS-CoV-2 nucleocapsid protein. Therefore, in this work we developed and characterized a series of new mouse monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein. The anti-nucleocapsid monoclonal antibodies were tested in ELISA, western blot, and immunofluorescence analyses. The variable regions from the heavy and light chains from five select clones were cloned and sequenced, and preliminary epitope mapping of the sequenced clones was performed. Overall, the new antibody reagents described here will be of significant value in the fight against COVID-19.Competing Interest StatementThe authors have declared no competing interest.